Newswise — March 15, 2022 - For patients recovering from fracture fixation surgery, dietary supplementation with conditionally essential amino acids (CEAA) reduces complications and prevents skeletal muscle wasting, concludes a clinical trial in The Journal of Bone & Joint Surgery. The journal is published in the Lippincott portfolio in partnership with Wolters Kluwer.

The study supports the use of widely available CEAA supplements to promote recovery and preserve function in patients undergoing surgery for repair of major fractures. "Our results suggest that this inexpensive, low-risk intervention has considerable potential to improve outcomes after fracture fixation," according to the report by Michael Willey, MD, and colleagues of University of Iowa Hospital and Clinics, Iowa City.

The CEAA supplement group had fewer complications with no loss of fat-free mass

The study included 400 patients undergoing operative fixation of fractures in the limbs and/or pelvis at the authors' trauma center. In equal numbers and stratified by fracture severity, patients were randomly assigned to either standard postoperative nutrition or standard nutrition plus CEAA supplementation.

CEAAs are termed "conditionally essential" because the body doesn't usually require them. However, during times of illness or stress, the need for these conditional amino acids increases dramatically. Previous studies have reported that CEAA supplementation can improve wound-healing and other outcomes in patients with a variety of conditions, including postoperative recovery. In the new trial, patients assigned to the CEAA group received a standard supplement that included arginine, leucine, and glutamine.

At follow-up, the overall complication rate was significantly lower for patients who received CEAA supplementation (30.5%) compared with those who did not receive CEAA (43.8%). The CEAA group also had a lower rate of nonunion (5.1 versus 13.2%, respectively). Some other types of complications, including surgical-site infections, were similar between groups.

Patients who undergo operative fracture fixation are at risk of skeletal muscle wasting, which often results in weight loss as a result of reduced muscle mass. In the new study, patients receiving CEAA supplements had little or no change in fat-free body mass. In contrast, patients receiving standard nutrition had a 1-kilogram reduction in fat-free mass at 6 weeks postoperatively, which took until 12 weeks to return to normal.

Unexpectedly, the CEAA group had a sharply reduced mortality rate (0.5% compared to 4.1 % in the control group). Although the authors could not explain the lower risk of death in patients receiving CEAA, they suggest it might result from "unidentified confounding factors."

Despite advances in surgical techniques, trauma patients undergoing operative fixation of extremity and pelvic fractures remain at risk of complications and prolonged loss of function. "Malnutrition is a potentially modifiable risk factor for mortality, fracture nonunion, wound complications, and increased length of stay," Dr. Willey and coauthors write.

These new results suggest that CEAA supplementation is a simple, risk-free, and inexpensive means of promoting good nutrition after fracture fixation surgery. After adjustment for other factors, the relative risk of complications is about 40 percent lower in patients receiving CEAA, with no reduction in fat-free mass during the early weeks of recovery. Dr. Willey and colleagues conclude: "This study will serve as the foundation for multicenter [randomized controlled trials] that are designed to assess the impact of CEAA nutrition supplementation in reducing complications and loss of functional muscle mass in high-risk populations."

Click here to read “Conditionally Essential Amino Acid Supplementation Reduces Postoperative Complications and Muscle Wasting After Fracture Fixation: A Randomized Controlled Trial“

DOI: 10.2106/JBJS.21.01014

###

About The Journal of Bone & Joint Surgery

The Journal of Bone & Joint Surgery (JBJS) has been the most valued source of information for orthopaedic surgeons and researchers for over 125 years and is the gold standard in peer-reviewed scientific information in the field. A core journal and essential reading for general as well as specialist orthopaedic surgeons worldwide, The Journal publishes evidence-based research to enhance the quality of care for orthopaedic patients. Standards of excellence and high quality are maintained in everything we do, from the science of the content published to the customer service we provide. JBJS is an independent, non-profit journal.

About Wolters Kluwer

Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.

Wolters Kluwer reported 2020 annual revenues of €4.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,200 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.

Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.

For more information, visit www.wolterskluwer.com, follow us on TwitterFacebookLinkedIn, and YouTube.

SEE ORIGINAL STUDY